Cystic fibrosis and survival;Mucoviscidose et survie: Quelle interprétation?

Revue des Maladies Respiratoires

Volumn 20, Issue 2 II, 2003, Pages

  Moreau, Th ^a  

^a INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL SURVIVAL; BURKHOLDERIA CEPACIA; CONFERENCE PAPER; CYSTIC FIBROSIS; DENMARK; DIAGNOSTIC TEST; GRAM NEGATIVE INFECTION; HIGH RISK POPULATION; HUMAN; INCIDENCE; KAPLAN MEIER METHOD; MORTALITY; NONHUMAN; POPULATION RESEARCH; PSEUDOMONAS AERUGINOSA; RESPIRATORY TRACT INFECTION; SURVIVAL;

EID: 0042230644     PISSN: 07618425     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (20)

1. Dodge JA, Morison S, Lewis PA, Coles EC, Geddes D, Russell G, Littlewood JM, Scott MT: Incidence, population, and survival of Cystic fibrosis in the UK, 1968-95. UK Cystic fibrosis Survey Management Committee. Arch Dis Child 1997; 77: 493-6.
2. Fitzsimmons SC: The changing epidemiology of Cystic fibrosis. J Pediatr 1993; 122: 1-9.
3. Rault G, Guilloud-Bataille M, Feingold J: Mucoviscidose: analyse comparative des données épidémiologiques des observatoires français et nord-américains. Rev Pneumol Clin 1995; 51: 115-21.
4. Delaisi B, Grosskopf C, Reignault E, Goehrs JM, Navarro J: Registre international sur la mucoviscidose: comparaison des données françaises avec les données européennes pour 1995. Arch Pediatr 1998; 5: 384-8.
5. Elborn JS, Shale DJ, Britton JR: Cystic fibrosis: current survival and population estimates to the year 2000. Thorax 1991; 46: 881-5.
6. Lannefors L, Lindgren A: Demographic transition of the Swedish Cystic fibrosis community-results of modern care. Respir Med 2002; 96: 681-5.
7. Fogarty A, Hubbard R, Britton J: International comparison of median age at death from Cystic fibrosis. Chest 2000; 117: 1656-60.
8. Corey M, Farewell V: Determinants of mortality from Cystic fibrosis in Canada, 1970-1989. Am J Epidemiol 1996; 143: 1007-17.
9. Commenges D, Letenneur L, Joly P, Alioum A, Dartigues JF: Modelling age-specific risk: application to dementia. Statist Med 1998; 17: 1973-88.
10. Emerson J, Rosenfeld M, McNamara S, Ramsey B, Gibson RL: Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with Cystic fibrosis. Pediatr Pulmonol 2002; 34: 91-100.
11. O'Connor GT, Quinton HB, Kahn R, Robichaud P, Maddock J, Lever T, Derzer M, Brooks JG. Case-mix adjustment for evaluation of mortality in Cystic fibrosis. Pediatr Pulmonol 2002; 33: 99-105.
12. Sharma R, Florea VG, Bolger AP, Doehner W, Florea ND, Coats AJ, Hodson ME, Anker SD, Henein MY. Wasting as an independent predictor of mortality in patients with Cystic fibrosis. Thorax 2001; 56: 746-50.
13. Aurora P, Wade A: Wasting as predictor in CF. Thorax 2002; 57: 468.
14. Szaff M, Hoiby N, Flensborg W: Frequent antibiotic therapy improves survival of Cystic fibrosis patients with chronic Pseudomonas aeruginosa infection. Acta Paediatr Scand 1983; 72: 651-7.
15. Frederiksen B, Lanng S, Koch C, Hoiby N: Improved survival in the Danish center-treated Cystic fibrosis patients: results of aggressive treatment. Pediatr Pulmonol 1996; 21: 153-8.
16. Corey M: Survival estimates in Cystic fibrosis: snapshots on a moving target. Pediatr Pulmonol 1996; 21: 149-50.
17. Corey M: Modeling survival in Cystic fibrosis. Thorax 2001; 56: 743.
18. Stern RC: Denmark to the rescue. Pediatr Pulmonol 1996; 21: 151-2.
19. Frederiksen B, Koch C, Hoiby N: Changing epidemiology of Pseudomonas aeruginosa infection in Danish Cystic fibrosis patients (1974-1995). Pediatr Pulmonol 1999; 28: 159-66.
20. Nir M, Lanng S, Johansen HK, Koch C: Long term survival and nutritional data in patients with Cystic fibrosis treated in a Danih center, Thorax 1996; 51: 1023-7.